Women have awaited a revolution in menopause. It hasn’t arrived.

Persistent barriers are still hindering drug development for a host of menopause symptoms.

By Kelly Bilodeau • April 8, 2026

Gilead could potentially end HIV. But will it be able to?

After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.

By Meagan Parrish • March 20, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Inside the race to thwart the dramatic rise in early-onset colorectal cancer

The increasingly common disease still presents a major challenge in oncology.

By Kelly Bilodeau • March 4, 2026

J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks

Spravato became a blockbuster despite ketamine’s dangerous abuse history, causing doctors to balance the real-world implications of its use.

By Michael Gibney • March 3, 2026

Biohaven says FDA roadblocks leave rare disease patients in limbo

An FDA rejection last year for a rare disease drug from Biohaven reflects the amount of work left to get patients the treatments they need, the company says.

By Michael Gibney • Feb. 26, 2026

Pharma’s outlook in 2026: Smoother sailing ahead?

After a turbulent year, the industry has a clearer picture of its new landscape and how to navigate the challenges and opportunities ahead. 

By Meagan Parrish • Jan. 30, 2026

Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs

The GLP-1 giants are the first to try out this new model, but more companies may follow. 

By Kelly Bilodeau • Jan. 14, 2026

PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D

Industry execs foresee drug innovation and AI breakthroughs in 2026.

By Meagan Parrish • Jan. 9, 2026

Another genetic testing company? Why a different approach could boost drug predictions and R&D.

Genetic tests could soon play a larger role in clinical trials and predicting adverse events.

By Alexandra Pecci • Dec. 10, 2025

FDA conflicts of interest extend beyond adcomm experts

Many speakers at public meetings report conflicts while showing support for new drugs, according to recent analysis.

By Meagan Parrish • Dec. 5, 2025

A drugmaker charts a path through pharma’s ethical minefields

As the science behind pharma breakthroughs becomes more complex, bioethicists are helping companies navigate moral quandaries.

By Kelly Bilodeau • Dec. 1, 2025

As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones

Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.

By Kelly Bilodeau • Nov. 19, 2025

Pharma’s clinical trial diversity push faces a new threat

Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.

By Meagan Parrish • Nov. 7, 2025

Why a treatment older than the FDA is getting new regulatory scrutiny

MAHA-aligned patients and providers are pushing back to ensure access to an animal-derived thyroid hormone treatment.

By Kelly Bilodeau • Oct. 20, 2025

Pregnant women, long excluded from drug trials, are back in the spotlight

The White House has raised concerns around women’s health, but R&D on pregnant and breastfeeding women is still lacking.

By Meagan Parrish • Oct. 17, 2025

Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?

This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.

By Michael Gibney • Oct. 2, 2025

AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others

FluMist Home could be a test case for at-home vaccines against a backdrop of challenging regulatory shifts.

By Alexandra Pecci • Oct. 1, 2025

Top pharma industry conferences in 2026

Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.

By Meagan Parrish • Updated Jan. 26, 2026

As obesity M&A heats up, pharmas could get ‘blinded by opportunity’

With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.

By Kelly Bilodeau • Sept. 29, 2025

From atop Mt. Fuji, a Takeda team heralds a need for human plasma

The climb aimed to raise money and awareness as Takeda ramps up its plasma-derived therapy presence in Japan.

By Alexandra Pecci • Sept. 16, 2025

4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next

The company scored the first-ever approval to treat a potentially deadly infection leveraging its gene therapy platform.

By Meagan Parrish • Sept. 12, 2025

Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.

Growing research suggests various ways weight loss drugs could have an impact in cancer care.

By Michael Gibney • Sept. 11, 2025

Inside pharma’s race to deliver new treatments for dwarfism

By targeting the underlying genetic mutation that drives the condition, researchers hope to increase height and address debilitating complications.

By Kelly Bilodeau • Sept. 8, 2025

At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves

Robert F. Kennedy Jr. faced criticism Thursday even from Republican lawmakers over changes to federal vaccine policy as well as a leadership crisis at the CDC.

By Delilah Alvarado , Jonathan Gardner • Sept. 5, 2025

Why an FDA decision for a new drug could ripple through the ultra-rare disease space

All eyes are on Stealth BioTherapeutics as it awaits a long-delayed approval for its first-in-class treatment for Barth syndrome.

By Alexandra Pecci • Aug. 26, 2025